BethBio provides innovative bioinformatic solutions to empower the development of novel and better vaccines, including virus evolution prediction and more.
Our recent article on predicting influenza virus evolution is now featured in Nature Communications Editors’ Highlights (https://t.co/IGYGGjm6L5) in the profile of Public Health.
BethBio announced that on March 2023, we have become a resident of Johnson & Johnson Innovation ��� JLABS @ Shanghai. The company is working on new vaccine development with pharmaceutical companies using our novel solutions, such as viral mutation prediction and epitope screening.
A research project of real-time evaluation of COVID-19 vaccine effectiveness by the JC School of Public Health and Primary Care (JCSPHPC) is in discussion to be adopted by Singapore authorities to inform policy decision making.
https://t.co/qvZuaW9pCm
2022/10/14
Healthcare Innovation and Technology Summit 2022(HITS 2022) was held in Hong Kong Science Park.
Beth was invited as an exhibitor. We met plenty of industry leaders. Thank you for the speech given by
Professor CHAN and Mr. Albret Wong.
https://t.co/zhXG0c6vvg
#HKSTP
5/ For @GaviSeth, increasing vaccine uptake requires a systems approach:
“If we want to get universal health coverage, we need primary health care. Investing in vaccination is the most cost-effective way to improve primary health care and to reach zero-dose children.”
Enjoyed visiting the Adama Regional Vaccines Store in Ethiopia with Dr @lia_tadesse, and @dr_zelalem to get a better understanding of the supply chain processes, as well as vaccine logistics and any constraints impeding vaccine coverage. #VaccinesWork
No country in Europe has reached the 75% #flu vaccination target yet. We all have a role to play to increase flu vaccination uptake and protect people’s health https://t.co/65IP5OCEVs #WeWontRest
The @EMA_News has accepted a variation for the evaluation of a 50 µg #booster dose of the Omicron-containing bivalent COVID booster candidate, mRNA-1273.222, in adults 12 years and older. Read more: https://t.co/S2ZJgg4NQE
We and our partner @pfizer completed the regulatory submission for our #Omicron BA.4/BA.5-adapted bivalent #COVID19vaccine for children 5-11 years of age to @EMA_News - only a few days after the submission to @US_FDA.
Although vaccination is highly cost-effective, budgets for prevention are low across the EU. Increasing investment in vaccination could improve #VaccinesSupply and #access https://t.co/XZsaPt0j4c #RC6#WeWontRest
NEW from our print issue #ICYMI: Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based #antibiotics and case their future into doubt.
https://t.co/WsETOodwck
Beautiful profile of Prof. Juliana Chan @CUHKMedicine just published in @DiabetesCareADA by @DrRonaldMa1 and colleagues. So grateful to have had the opportunity to train with a legendary figure in #diabetes research, care, and education! https://t.co/qCugduNWB0
We have published updated #COVID19 vaccine data supporting efficacy and safety in children from 6 months through 4 years of age. The updated analysis showed 73.2% vaccine efficacy and a favorable safety profile. https://t.co/QAjdn8xGWK
We completed, together with @Pfizer, the submission to the @US_FDA requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children aged 5-11. https://t.co/R6A2LfZtgb
An automated cold chain logistic center that SINOVAC donated to #VACSERA Egypt recently opened and the first batch of vaccines went into storage last Saturday. The facility can store 150 million doses and will contribute to the improvement of public health in #Egypt and #Africa.